newsfilter
← Latest News
Business Wire·

Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026

  • Faeth Therapeutics (Nasdaq: FTH) will host a virtual event on Monday, November 9 at 8:00 AM ET to discuss topline results from its Phase 2 PIK-201 trial.
  • The event will feature PIK-201 principal investigator David Starks, MD, MPH, alongside company management to discuss the treatment landscape in advanced endometrial cancer.
  • A live question-and-answer session will follow the formal presentations.
  • PIKTOR is an investigational all-oral combination of serabelisib (PI3K-alpha inhibitor) and sapanisertib (mTORC1/mTORC2 inhibitor) designed to inhibit multiple nodes of the PAM pathway.
  • The Phase 2 PIK-201 trial evaluates PIKTOR in second-line advanced endometrial cancer.
  • PIKTOR is also being evaluated in a Phase 1b/2 trial (Study FTH-PIK-101) for HR+/HER2- advanced breast cancer, where the first patient was dosed in April 2026 with interim data anticipated in 2027.
  • Faeth Therapeutics was co-founded in 2019 by Anand Parikh, Oliver Maddocks, Ph.D., and scientific founders including Lewis Cantley, Ph.D., Siddhartha Mukherjee, M.D., D.Phil., Karen Vousden, Ph.D., Scott Lowe, Ph.D., and Greg Hannon, Ph.D.
  • The press release includes forward-looking statements regarding development plans, data timing, and potential benefits, noting risks related to clinical trial results, financing, and regulatory compliance.